Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India by Saumya Srivastava et al.
RESEARCH Open Access
Laboratory confirmed miltefosine resistant
cases of visceral leishmaniasis from India
Saumya Srivastava, Jyotsna Mishra, Anil Kumar Gupta, Amit Singh, Prem Shankar and Sarman Singh*
Abstract
Background: Miltefosine unresponsive and relapse cases of visceral leishmaniasis (VL) are increasingly being reported.
However, there has been no laboratory confirmed reports of miltefosine resistance in VL. Here, we report two laboratory
confirmed cases of VL from India.
Methods: Two patients with VL were referred to us with suspected VL. The first patient was a native of the VL endemic
state of Bihar, but residing in Delhi, a VL non-endemic area. He was treated with broad-spectrum antibiotics and
antipyretics but was unresponsive to treatment. The second patient was from Jharkhand state in eastern India (adjoining
Bihar), another endemic state for VL. He was refractory to anti-leishmanial treatment, which included administration of
miltefosine. Following investigation, both patients were serologically positive for VL, and blood buffy coat from both
patients grew Leishmania donovani. The isolates derived from both cases were characterized for their drug susceptibility,
genetically characterised, and SNPs typed for LdMT and LdROS gene expression. Both patients were successfully treated
with amphotericin B.
Results: The in vitro drug susceptibility assays carried out on both isolates showed good IC50 values to amphotericin B
(0.1 ± 0.0004 μg/ml and 0.07 ± 0.0019 μg/ml). One isolate was refractory to SbIII with an IC50 of > 200 μM while
the second isolate was sensitive to SbIII with an IC50 of 36.70 ± 3.2 μM. However, in both the isolates, IC50 against
miltefosine was more than 10-fold higher (> 100 μM) than the standard strain DD8 (6.8 ± 0.1181 μM).
Furthermore, genetic analyses demonstrated single nucleotide polymorphisms (SNPs) (354Tyr↔Phe and
1078Phe↔Tyr) in the LdMT gene of the parasites.
Conclusions: Here, we document two laboratory confirmed cases of miltefosine resistant VL from India. Our
finding highlights the urgent need to establish control measures to prevent the spread of these strains. We also
propose that LdMT gene mutation analysis could be used as a molecular marker of miltefosine resistance in L.
donovani.
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Background
Human visceral leishmaniasis (VL), commonly known as
kala-azar, is a serious medical and public health issue in
India, the Mediterranean region, and in parts of southern
Europe, Africa, and South America where it is recognised
as a neglected tropical disease [1, 2]. In India, the causa-
tive protozoan parasite is Leishmania donovani [3]. The
parasite is transmitted via the bite of a female sand fly
from the genera Lutzomyia and Phlebotomus [1, 3]. The
clinical manifestation of leishmaniasis ranges from
asymptomatic to fulminant that can progress to a highly
fatal form, if untreated. VL is typically characterized by
fever, weakness, progressive weight loss, pancytopenia,
and massive hepato-splenomegaly [3].
The first line treatment of VL has been the pentavalent
antimonials [sodium antimony gluconate (SAG)] [4].
However, in the last four decades, resistance to SAG has
increased to alarming levels, particularly in some parts
of India, forcing the national government to stop using
of SAG [5]. Currently, the therapeutic options available
for VL include amphotericin B (deoxycholate, liposomal
or other formulations) and miltefosine [4]. Amphotericin
B is highly effective in treating antimony-resistant cases
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[4] but its nephrotoxic side effects and the high cost of
liposomal formulations restricts its wider use [6, 7]. Milte-
fosine, the first oral drug, was licensed for the treatment
of VL in 2002 with reported cure rate of 98% [3, 5]. Cur-
rently, miltefosine is reported to be safe and well tolerated
by adults and children [8] and plays a key role in India’s
kala-azar elimination program, which aims to reduce the
incidence of VL to less than 1 case per 10,000 in the next
five years [9].
Recently, there have been an increasing number of
cases of unresponsiveness to miltefosine and/or reduced
efficacy in the treatment of VL in India and Nepal [9, 10].
Miltefosine is an alkyl-phospholipid, an analogue of
phosphocholine. Its chemical similarity to the natural
phospholipids of cellular membrane suggests that miltefo-
sine probably inhibits transmembrane signals and the syn-
thesis of the cellular membrane. The exact mode of its
action and the developing resistance is not well known.
The uptake of miltefosine in Leishmania spp. parasites in-
volves the Leishmania membrane protein, Leishmania
donovani miltefosine transporter (LdMT), a member of
the P4 subfamily of P-type ATPases, and LdRos, a poten-
tial non-catalytic β subunit of LdMT. Both proteins are
primarily localized in the Leishmania plasma membrane
and are required for the rapid intracellular uptake of alkyl-
phosphocholine drugs. LdMT and LdRos form a stable
protein complex, which facilitates the translocation of
phospholipids in the parasite from the exoplasmic sites to
the cytoplasmic sites of the plasma membrane [11–14]. It
is reported that even a single point mutation within the
two alleles of the LdMT gene are responsible for the resist-
ant phenotype through inactivation of the transporter pro-
tein [15, 16]. Consequently, mutational changes in LdMT
(specifically, 856Leu↔Pro, 420Thr↔Asn, and 832Leu↔Phe)
have shown an increased rate of resistance in both in vitro
and in vivo conditions [11, 12]. These mutations result in
decreased uptake, increased efflux, faster metabolism
[15, 17], and changes in the lipid composition of the
parasite membranes [18]. Other mutations identified
in the miltefosine resistant L. donovani include W210
(in LdMT) and M1 (in LdRos) [19] and single nucleo-
tide polymorphisms (SNPs), 527T↔A, which results in
the substitution of 176Val↔Asp in LdMT gene [20].
Although miltefosine resistant strains of L. donovani
have not yet been cultured or isolated from the Indian
subcontinent [10, 21], parasites with varying degree of
miltefosine susceptibility have been reported [19]. In the
absence of miltefosine resistant clinical isolates, the only
option to study the mechanisms of miltefosine resistance
has been to create in vitro resistant strains [14, 20, 22].
Recently, a case of VL was reported from Nepal with
clinical relapse after successful treatment with miltefosine;
however, the parasite could not be isolated from the
patient [23]. Two cases of miltefosine unresponsive
cutaneous leishmaniasis are also on record; one from
Ecuador and another from Venezuela, but again without
isolation of the parasite [24, 25]. Here we are reporting
two cases of laboratory confirmed miltefosine resistant VL
(L. donovani) from the VL endemic area of India with
phenotypic and genotypic characterization of the isolates.
Methods
Patient history
Two patients with suspected drug-resistant VL were
referred to our laboratory for confirmatory diagnosis in
the first 6 months of 2011. Both patients were from VL
endemic areas. The first patient (LD843) was a 12-year-
old boy native to the Patna district of Bihar (Fig. 1), but
who had been residing in Delhi (a VL non-endemic area)
for more than 5 years, although he frequently returned
to his native village in Bihar. Referred in March 2011
from the Kalawati Saran Children Hospital, New Delhi,
the patient had started having a high-grade fever for the
past 20 days, which was not responding to antipyretics
and broad-spectrum antibiotics (given locally). On clin-
ical and laboratory examination, he was found to have
moderate hepato-splenomegaly and was severely an-
aemic with haemoglobin levels of 5.2 g/dl [normal range
(NR) 12–14 g/dl]. The patient had previously visited his
native village in Bihar in November 2010.
The second patient (LD860), a 37-year-old man from
the Deogarh District of Jharkhand (Fig. 1), was referred
in April 2011. This individual presented at a local hospital
in Jharkhand in November 2009, with complaints of loss of
appetite and body weight. LD860 had a history of persistent
fever for more than two weeks that was refractory to
antipyretics and antibiotics. On clinical examination, the
patient was anaemic, febrile, had moderate hepato-
splenomegaly, with a palpable liver and spleen measuring
142 and 152 mm, respectively. He had a white blood cell
count of 10,600 mm3 (NR 4,000–10,000 mm3), haemoglo-
bin of 8.6 g/dl (NR 12–14 g/dl), with 50% neutrophils (NR
40–70%) and 44% lymphocytes (NR 20–35%). Following a
positive serum aldehyde test for VL, in January 2010 SAG
was administered at 20 mg/kg/day for a period of 21 days.
Within 5 days his general condition improved and the pa-
tient became afebrile. However, after 6 months (August
2010) his clinical symptoms returned. At this point, he was
severely anaemic with haemoglobin levels of 5.2 g/dl,
leukocyte count of 8,800 mm3, with 63% neutrophils and
34% lymphocytes. Bone marrow aspirates showed an abun-
dant number of Leishman-Donovan (LD) bodies. This time
the patient was administered amphotericin B at 1.0 mg/kg/
day for 15 days. However, treatment was interrupted due to
poor tolerance. The clinical and laboratory signs of VL per-
sisted and his repeat bone marrow remained positive for
LD bodies. The patient’s liver enzymes were significantly in-
creased with an SGPT value of 92 IU/l (NR 0–41 IU/l) and
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serum bilirubin of 2.6 mg/dl (NR 0.2–1.0 mg/dl). However,
after cessation of amphotericin B treatment, his haemoglo-
bin increased to normal limits i.e. 11.7 g/dl. In September
2010, miltefosine was administered to the patient at a dose
of 50 mg/twice a day for 28 days. Although the patient be-
came afebrile within a week and the laboratory findings
were satisfactory, his liver enzymes and bilirubin levels
remained high, for which he was given nutritional supple-
ments and managed symptomatically. Again, in February
2011, the patient complained of fever, jaundice, and heavi-
ness in the right subcostal region. Laboratory investigations
revealed increased liver enzymes [SGOT] and reversed
albumin-globulin ratio. Ultrasonography of the abdomen
showed mild hepatomegaly and moderate splenomegaly.
Finally, on 8th April 2011, the local physician referred the
patient to the All India Institute of Medical Sciences, New
Delhi, for further investigation and management.
Both patients underwent thorough laboratory investi-
gations at the All India Institute of Medical Sciences,
New Delhi. Sampling was conducted by the expert phle-
botomist in the institute’s central collection facility and
sent to us for routine investigations, including for leish-
maniasis. The patient’s serum samples were tested by
anti-rK39 dipstick test (kala-azar Detect™ Rapid Test, In
Bios International, Inc., Seattle, WA, USA) and anti-
rKE16 spot test (Signal®-KA, and Crystal® KA, Arkray
Healthcare Private Limited [formerly Span Diagnostics
Limited], Surat, Gujarat, India The latter tests are based
on a novel recombinant antigen [26] prepared from the
Indian strain (KE16) of L. donovani (MHOM/IN/1998/
KE16). Both are commercially available rapid tests and
approved by the Government of India for confirmatory
diagnosis of leishmaniasis. The Signal®-KA flow through
spot test and Crystal® KA (rKE16) lateral flow dipstick
Fig. 1 Map of India with highlighted VL endemic states of Bihar and Jharkhand (red). The map also shows the places from where two cases of
miltefosine resistant VL are reported in this study
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test and kala-azar Detect™ Rapid Test (rK39) [27] were
strongly positive. The aetiological agent of disease was
further confirmed by microscopic demonstration of LD
bodies in smears prepared from blood buffy coat. A
samples of blood buffy coat from both the patients were
used for isolation of the parasite on Novy-MacNeal-
Nicolle (NNN) medium.
Parasite culture
To prepare NNN medium, 1.4 g of agar and 0.6 g of
NaCl were suspended in 90 ml of distilled water, which
was then autoclaved at 121 °C for 20 min. The solution
was cooled to 50 °C before 10 ml of defibrinated rabbit
blood was added. Two and a half ml of the mixture was
then aliquoted into 7 ml Bijou tubes and allowed to cool
and solidify at room temperature and finally stored at
4 °C. One aliquot was used for quality control. Just
before inoculating the sample, 2 ml of M199 medium,
supplemented with 20% v/v heat inactivated foetal
bovine serum (FBS) and antibiotic solution containing
50 μg/ml gentamicin (Sigma-Aldrich, St. Louis, Missouri,
USA) and 100 μg/ml of streptomycin sulphate salt
(Sigma-Aldrich, St. Louis, MO, USA), was added. After
that, buffy coat samples (washed two times with 1× PBS)
were inoculated in NNN media and transferred to bio-
chemical oxygen demand incubator (BOD) to incubate at
25 °C. Fungal contamination was checked after 4 days,
and repeated every 4 days therefore to monitor the growth
of Leishmania spp. until day 30th of inoculation. The cul-
ture was then passaged every seven days into fresh NNN
medium. Parasites were then progressively adapted to
medium M-199 supplemented with 10% FBS, gentamycin
and streptomycin (complete medium) for mass culture.
Each isolate was typed to the level of species using
sequence data from the internal transcribed spacer (ITS)
of DNA, following PCR (see below). The isolates were
then characterized for their drug susceptibility. The para-
sites were tested for their in vitro susceptibility to standard
anti-leishmanial drugs within ten passages from isolation.
Both the isolates were subjected to nucleotide sequencing
and SNPs analysis of LdMT and LdRos gene using Torrent
variant caller software v5.0.1, as detailed below.
Genetic characterization of species
Parasite DNA from both clinical samples were subject to
PCR amplification of Leishmania-specific ITS regions. In
brief, total genomic DNA was isolated from blood buffy
coat using a DNeasy Blood & Tissue Kit (Qiagen, Hil-
den, Germany), as per manufacturer’s instructions. The
complete ribosomal ITS region (~1.1 kb) was then amp-
lified using Leishmania-specific primers (forward, 5'-
CTG GAT CAT TTT CCG ATG-3'; and reverse, 5'-ACA
CTC AGG TCT GTA AAC-3') [28]. The amplification
was performed in the thermal cycler (Eppendorf,
Hamburg, Germany) and initially heated to 95 °C for
2 min followed by 34 cycles of 95 °C for 20 s, 53 °C for
30 s and 72 °C for 1 min. The final extension was carried
out at 72 °C for 1 min. The PCR amplicon was excised
for purification using the QIAquick Gel Extraction Kit
(Qiagen, Hilden, Germany) from a 1.8% agarose gel pre-
pared in 1× TAE buffer, The purified PCR amplicon was
then sequenced using the ABI Prism Big Dye Terminator
v1.1 Cycle Sequencing Kit (Applied Biosystems, CA,
USA).
In vitro drug susceptibility test (MTT Assay)
The promastigote viability of the isolates (LD843 &
LD860) compared to standard strain DD8, (routinely
maintained and passaged in vivo in Syrian hamster to
maintain virulence and infectivity) [29] was determined
against 3 standard drugs using the MTT assay [30]. Cells
(1 × 104 cells/100 μl/well) were incubated in flat bot-
tomed 96-well plate (Nunc, Roskilde, Denmark) using
different concentrations of SbIII, an active component of
SAG [4], amphotericin B and miltefosine for 48 h at 26 °
C. The drugs were obtained from Sigma-Aldrich (SbIII),
Lifecare Innovations Gurgaon, Haryana, India (Ampho-
tericin B), and Zentaris Frankfurt, Germany (Miltefo-
sine). In brief, stock solutions of all three drugs were
dissolved in sterile distilled water. Each was further seri-
ally diluted up to seven-fold with freshly prepared
complete medium and incubated as described above for
48 h at 26 °C in a BOD incubator. After 48 h of incuba-
tion, 25 μl of sterile MTT (5 mg/ml dissolved in 1× PBS)
was added to each well and plates were incubated for
2 h at 37 °C. After incubation, 150 μl of pure dimethyl
sulfoxide (DMSO) was added in each well to stop the re-
action. The absorbance was measured in a microplate
reader at 570 nm wavelengths. The inhibitory effect of
the specific drug was expressed as 50% inhibitory con-
centration (IC50), i.e. the concentration of a drug which
is required for 50% inhibition of cell viability compared
to the control cells in culture medium without drugs.
The IC50 was calculated from the graph showing differ-
ent concentrations of the standard drugs plotted against
percentage cell growth. Each test was performed in du-
plicate with three independent experiments.
Anti-amastigote assay
The J-774A.1 mouse macrophage cell line was used to
evaluate the activity of miltefosine against intracellular
amastigotes transformed from clinical isolates. This was
then compared against the WHO standard strain DD8,
which is a pan-susceptible strain, isolated in 1968.
Amastigote studies against SAG and amphotericin B
were not conducted because the promastigote stage of
clinical isolates was sensitive to these drugs. Cells were
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seeded in 16-well tissue culture chamber slides at a
density of 4 × 104 cells/ml in RPMI 1640 medium with
10% FBS. The slides were incubated at 37 °C with 5%
CO2. After 24 h the medium was replaced with medium
containing meta-cyclic promastigotes at a macrophage/
parasite ratio of 1:10. This ratio allows promastigotes to
be engulfed by macrophages and transformed into amas-
tigotes with in 24 h. After 24 h of incubation at 37 °C
with 5% CO2,one slide was fixed in 100% methanol and
stained using Giemsa to determine the initial level of in-
fection. Once a satisfactory level of infection was
achieved, slides were exposed to miltefosine at doses of
100, 50, 25, 12.5, 6.25 and 3.12 μM (in duplicate) and in-
cubated for 48 h at 37 °C and 5% CO2. Following incuba-
tion, slides were stained with Giemsa and microscopically
examined. Parasite burden was calculated as [the percent-
age of infected macrophages × (mean number of amasti-
gotes/macrophage)] and compared to the parasite burden
in untreated infected control cells. Most of the macro-
phages were destroyed at higher concentrations of milte-
fosine (> 25 μM) and could not be evaluated. The results
were calculated as the percent inhibition of the total para-
site burden, and the IC50 was calculated from the graph
showing different concentrations of miltefosine plotted
against percentage inhibition. These tests were performed
in duplicate with three independent repeats.
Whole genome sequencing, assembly and SNPs analysis
of LD843
For genome analysis, total genomic DNA (gDNA) was
extracted from LD843 strain using the Qiagen Genomic
DNA Extraction Kit (Qiagen, Hilden, Germany). The in-
tegrity and purity of gDNA was analysed on a 0.8% agarose
gel prepared in 1× TAE. The whole-genome sequencing of
LD843 strain was carried out using 2 × 400 bp paired-end
reads using an Ion Torrent Personal Genome Machine
(PGM, Thermofisher, MA, USA) and the sequencing chip
316v2 (Thermofisher, MA, USA). Low quality and adopter
sequences were removed from the reads based on the
phred quality score (Q-30) of individual bases. Reads were
assembled into longer scaffolds using SPAdes assembly
v3.1 [31]. Miscalled single bases and insertions/deletions
(indels) in the assembled contigs were corrected with It-
erative Correction of Reference Nucleotides (iCORN) soft-
ware [32]. The sequence quality and read-depth coverage
analysis were completed using Torrent coverage analysis
v4.2 software [33]. The Integrative Genomics Viewer
(IGV) [34] was used to visualize the individual reads for
the analysis of read and mapping quality of contigs.
Non-mapping and replica reads were removed from
the assembled reads based on lower mapping quality
scores BQ (< 30). Sequencing analysis for LD860 is pres-
ently in process.
SNPs analysis of the gene(s) involved in miltefosine
resistance
SNPs analysis was carried out following alignment of
the reference sequences for LdMT and LdRos gene se-
quences with the de novo aligned sequence of LD843
using Torrent variant caller software v5.0.1 [35] The
regions which had a read depth of less than 100-fold
coverage and a maximum of three polymorphisms in
any given seven base regions were selected as candi-
date variable sites, while INDELs were identified with
the Variant caller v5.1 software. The accepted read
coverage of the variant bases were > 3 for forward
and reverse strand and > 6 for SNP quality and mini-
mum one distant read from contig gap. CIGAR scores
displayed the mapping quality and SNPs for all reads
at a specific site. For heterozygous SNPs, the variant
BQ or CIGAR score was checked to make certain it
was not considerably worse than the reference geno-
type BQ. To reduce sequencing error, a series of
SNPs quality validation steps were adopted, including
poor-quality SNPs detection. The position of individ-
ual SNP was visualized using the IGV software for
the analysis of read depth, filtering quality, and haplo-
type score [34].
Statistical analysis
The data are shown as the mean and standard deviation
(± SD) of three independent experiments. The percent
cell viability and IC50 values were calculated using
Microsoft Excel 2007 (Microsoft Corp, WA, USA).
Results
Management of patients
Both patients received intravenous amphotericin B deox-
ycholate (1.0 mg/kg/day) for 15 days under strict med-
ical supervision. LD843 was treated at the Kalawati
Saran Children Hospital, New Delhi while LD860 was
treated at the All India Institute of Medical Sciences,
New Delhi. The treatment was successful with complete
remission of the clinical symptoms within 2 weeks. Both
patients were discharged from hospital. Their laboratory
parameters also returned to normal within one month.
The patients underwent routine medical checkups for
1 year following treatment. During this period neither of
the patient reported relapse of symptoms.
Characterization of the Leishmania spp.
Parasite DNA from both clinical samples was subjected to
PCR amplification (~1.1 kb) of the Leishmania specific
ITS region (Fig. 2). Sequencing of these amplicons and
subsequent comparison to publicly available sequence
data indicated that sequences determined here showed
99% similarity with the L. donovani isolates (NICD/IN/50;
accession number EU753224.2). Sequencing analysis,
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further confirmed that the cases were of L. donovani in-
fection. The sequences obtained from the ITS region of
DNA isolated from strain LD843 and LD860 have been
submitted to GenBank under accession nos. JQ029056.1
and JQ780821, respectively.
Drug susceptibility test
The IC50 for all three drugs (Sb
III, amphotericin B and
miltefosine) were determined by plotting drugs concen-
tration vs percentage cell growth. The DD8 strain was
found to be sensitive to all three drugs; IC50 values of
32.78 ± 1.74 μM, 0.1 ± 0.0028 μg/ml and 6.8 ±
0.1181 μM, respectively, were determined (Fig. 3). Both
the clinical isolates, LD843 and LD860, showed good
response to amphotericin B with IC50 values of 0.1 ±
0.0004 μg/ml and 0.07 ± 0.0019 μg/ml, respectively.
However, both isolates showed > 10-fold increase in IC50
(> 100 μM) to miltefosine, compared to the DD8 strain
(6.8 ± 0.1181 μM). In addition, LD860 was found to be
resistant to SbIII with an IC50 of > 200 μM, while LD843
was sensitive to SbIII with an IC50 of 36.70 ± 3.2 μM
(Fig. 3).
Anti-amastigote assay findings
All amastigote assays were carried out in the mouse
macrophage cell line J-774A.1 (Fig. 4a). As the promasti-
gote assays showed no resistance to SbIII and amphoteri-
cin B, the amastigote assays were only performed using
miltefosine. Like promastigotes, amastigotes also showed
that miltefosine had no inhibitory effect on these clinical
isolates. After 48 h, the percentage of parasites internal-
ized by macrophages was higher in both isolates com-
pared to those of the DD8 strain (Fig. 4b). After
exposure of cells to miltefosine, the clearance of the in-
ternalized amastigotes was almost complete DD8
(Fig. 4c). Interestingly, the percentage of parasites inter-
nalized by macrophages was slightly higher in both the
clinical isolates (Fig. 4d), but clearance of amastigotes in
the miltefosine treated cells was negligible (Fig. 4e). Both
the clinical isolates showed resistance to miltefosine and
had an IC50 value of > 25 μM when compared to DD8,
which had an IC50 value of 13.56 ± 4.17 μM (Fig. 5). All
the experiments were repeated in triplicate. There were
no significant differences between both the in vitro as-
says (P = 0.0485).
Whole genome sequencing and assembly of LD843
The whole genome sequencing performed using an Ion
PGM system produced a total genome length of
31,356,640 bp, or 31.35 Mb, at an average coverage of
23× depth (covering 99.76% of the genome), and a GC
content of 56.68%. The de novo assembled genome of
the LD843 strain of Leishmania consisted of 3,670 scaf-
folds, with the largest of these 137,235 bp, and an N50
of 21,796 and an N75 of 10,357 bp.
SNPs analysis of gene involved in miltefosine resistance
A total of 31,356,640 nucleotide from the de novo assem-
bled Leishmania genome (830.6× mean coverage depth of
reference) were aligned to the reference sequences of
LdMT (accession no. XM 003859320.1) and LdRos (acces-
sion no. FR799619.2) genes (Additional file 1). Twenty-
one variants (indels) were detected in LdMT, while 13
were detected in LdRos. In-depth analysis of all variants
conferred that five heterozygous SNPs were detected in
LdMT whereas no significant SNPs were detected in
LdRos. Three of the SNPs in LdMT were synonymous and
two were non-synonymous. As synonymous SNPs do not
affect the structural and functional activity of the protein,
we only focused on the two non-synonymous SNPs
(1061A↔T and 3233T↔A),which resulted in the substitu-
tions 354Tyr↔Phe and 1078Phe↔Tyr, respectively (Table 1,
Fig. 6). The nucleotide substitutions are significant and
perturb the protein’s structural stability. The nucleotide se-
quence of LdMT has been submitted to GenBank
(KX827627).
Fig. 2 PCR analysis of buffy coat sample from serologically positive
VL patients. Specific PCR product for ITS region of Leishmania spp.
(~1.1 kb product; arrow). Lanes 1, 2: PCR amplified products of DNA
extracted from the buffy coat of LD843 and LD860 patients
respectively; Lane 3: positive control (DNA extracted from DD8 strain
of L. donovani promastigotes); Lane 4: positive control (DNA
extracted from the buffy coat of known positive patient); Lane 5:
negative control (DNA from the buffy coat of healthy individual);
Lane 6: 1 kb molecular weight DNA ladder
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Discussion
Visceral leishmaniasis is highly fatal if not treated [36]. In
the absence of effective vaccines or vector control mea-
sures, the only option to control the disease is chemother-
apy. For the last few decades, antimonials have been the
predominant drugs of choice [4]. However, clinical
resistance to these drugs emerged in the late 1980s and has
become a principle obstacle in VL treatment and control
[4, 36, 37]. Moreover, severe cardiac toxicity has further
limited its use [38]. Alternative treatment options include
amphotericin B and miltefosine. Both have similar efficacy,
but miltefosine is an oral drug while amphotericin B
Fig. 3 Representative plots of susceptibility profile (IC50) of parasite isolates from VL cases and standard strain DD8 to (a) Miltefosine, b SAG (Sb
III)
and (c) Amphotericin B. Each individual graph represents the mean from three separate assays
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requires intravenous infusion and hospitalization. The lipo-
somal forms of amphotericin B are safer but prohibitively
costly [6, 39].
Although miltefosine was the preferred treatment
option for VL, with a cure rate as high as 98% [4],
the long course of disease treatment, and the longer
half-life (around 150 h), has rendered this drug highly
vulnerable to the development of resistance [40]. This
hypothesis is further supported by preliminary data of
the post phase 4 trials of miltefosine showing the
cure rate dropping to about 82–87% only [41]. Its
vulnerability is further proved with the fact that
miltefosine-resistant mutants of Leishmania can be
generated very easily in vitro [42].
Although the exact method by which miltefosine
resistance develops remains unknown, it is well docu-
mented that miltefosine uptake by Leishmania para-
sites involves multiple integral membrane proteins
including LdMT, a member of the P4 subfamily of P-
type ATPases, and LdRos, a potential noncatalytic β
subunit of LdMT [11–14]. These trans-membrane
proteins are required for the rapid intracellular uptake
Fig. 4 The in vitro miltefosine resistance demonstrated in clinical isolates using J774-A1 cell line. a Uninfected J774-A1 macrophages. b Macrophages
cells infected with DD8 strain but untreated with miltefosine showing amastigotes within macrophages. c Miltefosine-treated DD8 infected macrophages
showing clearance of amastigotes. d Macrophage cells infected with the clinical isolate but untreated with miltefosine and showing amastigotes within
macrophages. e Macrophages infected with clinical isolate and treated with miltefosine showing no effect on the clearance of amastigotes. Giemsa
stained macrophages cells were photographed at 1000× magnification using a light microscope
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of alkylphosphocholine drugs such as miltefosine. It is
conceivable that resistance may develop following the
occurrence of non-synonymous point mutations in
the genes coding for the respective proteins. Compari-
son of our genome sequence from strain LD843 with data
publicly available for LdMT (3,294 bp) and LdRos
(1,142 bp) revealed two novel SNPs in LdMT, 354Tyr↔Phe
and 1078Phe↔Tyr. Tyrosine and phenylalanine play a key
role in cell proliferation and differentiation via phosphoryl-
ation [43]. These non-synonymous SNPs in LdMT may
cause conformational changes in this structural protein
that may alter the plasma membrane and/or induced
changes to miltefosine uptake by the parasite leading to
the development of miltefosine resistance.
The present report highlights the existence of field
strains of VL in India that are resistant to miltefosine,
and provides laboratory confirmation of this finding.
The high IC50 of the clinical isolates indicates in vivo se-
lection of the miltefosine resistant clones. However, the
paediatric case is of rather more concern as it indicates
the possibility of transmission of the miltefosine resistant
strain in the neighbouring area within a span of a few
months only. The distance between Patna (Bihar) and
Deogarh (Jharkhand) is approximately 300 km.
Ultimately, this report sends a strong warning to VL
control programs and WHO that miltefosine-resistant
strains have emerged in India and that improved
methods of treatment and control are required in order
to prevent the spread of resistant strains to other areas
within and outside India.
Conclusions
Miltefosine was considered a highly effective oral drug
for the treatment of VL in India, but these two cases of
laboratory confirmed resistance in L. donovani against this
drug sends an urgent signal for the need to search for new
drugs or drug combinations. Although miltefosine induces
an early clinical response in patients, increasing numbers
of relapses indicate an urgent need for studying new drug
development and use of combination therapies. As cell-
mediated immunity against Leishmania parasites is com-
promised during the acute phase of VL, administration of
miltefosine with agents that are known to have immuno-
modulatory, effects can be a good choice. We also propose
that 354Tyr↔Phe and 1078Phe↔Tyr mutations in the
LdMT gene can be used as molecular markers of miltefo-
sine resistance in L. donovani.
Fig. 5 Representative plot of anti-amastigote assay of parasites isolated from kala-azar cases and standard strain DD8. The graph represents the %
inhibition and mean IC50 of the results from three separate assays
Table 1 Gene mutations identified in miltefosine resistant strain LD843
S. No. Chromosome no. SNP type Position in gene Reference base Reference cds Base in LD843 LD843 cds Amino acid change
1 13 Non-syn 1061 A TAC T TTC Y354F
2 13 Syn 1227 T CTA C CTC –
3 13 Syn 1267 T TTG C CTG –
4 13 Syn 2595 T GTT C GTC –
5 13 Non-syn 3233 T TTC A TAC F1078Y
Abbreviations: S serial; SNP single nucleotide polymorphism; cds codons; Syn synonymous; Non-syn non-synonymous
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Additional file
Additional file 1: Sequence alignment and SNPs analysis of LdMT
gene in LD843 strain (LdMT_M) with wild type sequence (LdMT_W).
(PDF 268 kb)
Abbreviations
DW: Distilled water; FBS: Foetal bovine serum; gDNA: Genomic DNA; IC50: 50%
inhibitory concentration; ITS: Internal transcribed spacer; LdMT: Leishmania
donovani miltefosine transporter; NR: Normal range; Phe: Phenylalanine;
SAG: Sodium antimony gluconate; SNP: Single nucleotide polymorphism;
Tyr: Tyrosine; VL: Visceral leishmaniasis
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